Aeglea BioTherapeutics Named Among Top 10 Innovative Cases in VB Insights' 2025 China Innovative Drug Industry White Paper
Evergreen Therapeutics
Innovative Drug Developer
Introduction
Recently, VCBeat released the "2025 Innovative Drug and Supply Chain Annual Innovation White Paper." The report concludes that China's innovative drug industry is currently entering a critical phase of deep differentiation and value regression. At the policy level, there is a focus on clinical value with precise guidance. Capital is being concentrated towards core technology platforms and global operational capabilities. Original innovation and substantial clinical breakthroughs have become the core logic driving high-quality industrial development.
Evergreen Therapeutics Successfully Selected as One of the Top Ten Innovative Excellence Cases of the Year with EG-501, the World's First AI-Driven Treatment for Cognitive Impairment in Neuropsychiatric Systemic Lupus Erythematosus.The positive outcomes achieved by EG-501 in Phase II clinical trials not only validate the practical effectiveness of the company's AI technology in precisely empowering clinical research and development, but also fully demonstrate the forward-looking vision and technical strength possessed by the company in the field of neuroinflammation, which is part of China's national strategic layout.
Arterial Intelligence observed that China's innovative drug industry is undergoing a shift in core logic, transitioning from pursuing speed and concepts to focusing on...Product Strength, Platform Strength, and Global Operational CapabilityA new era. To help the industry identify value and determine direction, VB Data, based on long-term industry insights, has released the "2025 Innovative Drug and Supply Chain Annual Innovation White Paper."
The following is an excerpt from the report:
Over a Hundred Chinese Companies Enter the AI Drug Development Space, Moving into the Value Realization Phase
Against the backdrop of accelerating changes in the global biopharmaceutical innovation paradigm, the deep integration of artificial intelligence and drug research and development has gone beyond the scope of being merely auxiliary tools.Field,But gradually evolved into a core infrastructure that reshapes industry logic and reconfigures value chains.Total Financing in China's AI Pharmaceutical Sector Shows Phased Correction in 2025, but Breakthrough Progress in Technology Platforms and Full...The capability of spherical output has reached a peak. Leading companies have achieved platform-based authorization from "molecular design" to "end-to-end R&D systems," driving China's AI pharmaceutical industry to leap from technical validation to value realization.
Platform Authorization Replaces Single Pipeline as the Mainstream of Value Monetization, AI Enters the Validation Phase as a "Research and Development Partner"
Capital and BD The prosperity ultimately requires clinical data validation.2025Year, entered the clinical stageAIThe significant increase in self-developed or collaborative pipelines by pharmaceutical companies demonstrates that AIThe practical effectiveness of technology in molecular design and drug potential has also shifted the industry's focus from "whether it can become a drug" to "how to improve success rates in clinical stages."
The key to realizing higher clinical value lies not only in addressing significant unmet clinical needs but also in achieving precise optimization of clinical solutions through the deep exploration and innovative application of cutting-edge biological mechanisms.。2025Year, the company that made landmark progress in this dimension isAIEvergreen Therapeutics Drives Innovation in the "Neuroimmunology" Field.
Breakthrough Progress of Evergreen Therapeutics Released, Closely Following2025Year6In the month, a new round of the "National Science and Technology Major Project for Innovative Drug Development" (hereinafter referred to as the "Innovative Drug Project") has officially started. The "Innovative Drug Project" aims to build a national drug innovation system, overcome key core technology bottlenecks, cultivate leading enterprises with international influence, and comprehensively enhance China's overall strength and international status in drug research and development.
Against this policy background, Evergreen Therapeutics announced its new drug under research.EG-501Treatment of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) The positive results of the Phase II clinical trial on cognitive impairment provide valuable practical reference for the "neuroimmunological" targeted treatment pathway.
EG-501As the world's first targetedNPSLEOral small molecule targeted drugs for cognitive impairment, with an innovative mechanism that selectively modulates neurons, precisely inhibiting pathologicalNMDAWhile mediating the excitotoxicity caused by receptor overactivation, it focuses on reducing neuroinflammatory burden and promoting synaptic function repair, thereby achieving a neuroprotective effect. The development pathway of this project is highly aligned with the strategic orientation of the "Innovative Drug Special Program."Its high alignment with unmet clinical needs,AIThe successful practices in platform-driven target discovery, in-depth exploration of new mechanisms in neuroinflammation, and efficient clinical translation are exemplary cases responding to the national deployment of scientific and technological innovation.。
EG-501Clinical progress not only providesNPSLEThe related cognitive impairment, a global clinical challenge, provides a breakthrough potential treatment solution, validating Evergreen Therapeutics' "Artificial Intelligence+The "Neuroimmunology" R&D paradigm has achieved an end-to-end closed loop from target discovery to clinical validation, further demonstrating its value as a replicable and scalable systematic innovation model.
To learn about the specific case content, please long press or scan the QR code in the figure below to obtain the full report.
*Cover image source: 123rf
Recommended Reading
